European Growth Companies With Strong Insider Ownership August 2026
As European markets experience a positive shift, driven by better-than-expected corporate earnings and renewed interest in AI-related stocks, investors are increasingly focusing on companies with strong insider ownership as a potential indicator of confidence and alignment with shareholder interests. In this context, growth companies that demonstrate robust insider ownership can offer valuable insights into their long-term prospects amidst the current economic climate.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| MilDef Group (OM:MILDEF) | 10.3% | 30.9% |
| Kuros Biosciences (SWX:KURN) | 26.1% | 61.1% |
| KebNi (OM:KEBNI B) | 11.8% | 90.9% |
| Hacksaw (OM:HACK) | 13.2% | 23.7% |
| Dellia Group (OB:DELIA) | 29.9% | 47.9% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 73.9% |
| CD Projekt (WSE:CDR) | 35.2% | 39% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.8% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 50.2% |
Let's explore several standout options from the results in the screener.
ITAB Group (OM:ITAB)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ITAB Group AB (publ) is involved in developing, manufacturing, selling, and installing store concepts for retail chain stores, with a market cap of SEK3.93 billion.
Operations: The company's revenue primarily comes from its Furniture & Fixtures segment, which generated SEK12.84 billion.
Insider Ownership: 25.4%
ITAB Group has shown strong insider confidence with substantial insider buying in the past three months. The company recently reported improved earnings, with net income rising to SEK 55 million for Q2 2026. Analysts expect ITAB's revenue and earnings growth to outpace the Swedish market, despite a forecasted slower revenue growth of 4.4% annually. A new EUR 8 million agreement for store solutions may bolster future performance, although ITAB carries a high level of debt.
- Click here and access our complete growth analysis report to understand the dynamics of ITAB Group.
- In light of our recent valuation report, it seems possible that ITAB Group is trading behind its estimated value.
Idorsia (SWX:IDIA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Idorsia Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for unmet medical needs across several regions including Switzerland, the United States, Japan, Europe, China, and Canada with a market cap of CHF1.56 billion.
Operations: Idorsia Ltd generates revenue through the discovery, development, and commercialization of pharmaceutical products targeting unmet medical needs across regions such as Switzerland, the United States, Japan, Europe, China, and Canada.
Insider Ownership: 24.1%
Idorsia's growth prospects are underscored by its expected revenue increase of 18.5% annually, surpassing the Swiss market average. Despite recent financial challenges, including a CHF 152.75 million net loss for H1 2026 and shareholder dilution, strategic moves like the QUVIVIQ distribution deal in Saudi Arabia and a CHF 250 million financing agreement enhance liquidity and potential growth avenues. Leadership changes with Roland Wandeler as CEO may further drive strategic execution in this volatile landscape.
- Unlock comprehensive insights into our analysis of Idorsia stock in this growth report.
- Our comprehensive valuation report raises the possibility that Idorsia is priced lower than what may be justified by its financials.
Formycon (XTRA:FYB)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Formycon AG is a biotechnology company that develops biosimilar drugs in Germany and Switzerland, with a market cap of €338.97 million.
Operations: The company's revenue segment is primarily from Biotechnology, amounting to €52.28 million.
Insider Ownership: 14.2%
Formycon's growth trajectory is highlighted by its significant revenue increase, with first-quarter sales reaching €13.1 million, up from €5.3 million year-on-year. The company anticipates further growth with projected 2026 revenues between €60 million and €70 million. Despite a net loss of €15 million in Q1 2026, Formycon's strategic launch of the Eylea biosimilar FYB203 across Europe supports its expansion plans. Insider ownership remains high, underpinning confidence in its long-term strategy amidst challenging market conditions.
- Navigate through the intricacies of Formycon with our comprehensive analyst estimates report here.
- Insights from our recent valuation report point to the potential undervaluation of Formycon shares in the market.
Key Takeaways
- Get an in-depth perspective on all 216 Fast Growing European Companies With High Insider Ownership by using our screener here.
- Searching for a Fresh Perspective? Trump's oil boom is here — pipelines are primed to profit. Discover the 23 US stocks riding the wave.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com